These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25164277)

  • 41. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular disease and PPARdelta: targeting the risk factors.
    Muscat GE; Dressel U
    Curr Opin Investig Drugs; 2005 Sep; 6(9):887-94. PubMed ID: 16187688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The prospects for the application of the natural and preformed therapeutic factors in the treatment of non-alcoholic fatty liver disease].
    Zabolotnaya IB
    Vopr Kurortol Fizioter Lech Fiz Kult; 2016; 93(4):42-48. PubMed ID: 27500678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].
    Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG
    Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
    Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
    Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
    Chen X; Matthews J; Zhou L; Pelton P; Liang Y; Xu J; Yang M; Cryan E; Rybczynski P; Demarest K
    Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial.
    Chen S; Zhao X; Wan J; Ran L; Qin Y; Wang X; Gao Y; Shu F; Zhang Y; Liu P; Zhang Q; Zhu J; Mi M
    Pharmacol Res; 2015 Sep; 99():74-81. PubMed ID: 26032587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future.
    Delitala AP; Delitala G; Sioni P; Fanciulli G
    Curr Med Res Opin; 2017 Nov; 33(11):1985-1993. PubMed ID: 28498022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ
    Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
    Li Z; Liao C; Ko BC; Shan S; Tong EH; Yin Z; Pan D; Wong VK; Shi L; Ning ZQ; Hu W; Zhou J; Chung SS; Lu XP
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3507-11. PubMed ID: 15177462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys.
    Wagner JD; Shadoan MK; Zhang L; Ward GM; Royer LJ; Kavanagh K; Francone OL; Auerbach BJ; Harwood HJ
    J Pharmacol Exp Ther; 2010 Jun; 333(3):844-53. PubMed ID: 20190014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.
    Bojic LA; Burke AC; Chhoker SS; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Tirona RG; Yin H; Pickering JG; Huff MW
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):52-60. PubMed ID: 24158519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Examining the safety of PPAR agonists - current trends and future prospects.
    Bortolini M; Wright MB; Bopst M; Balas B
    Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity.
    Le Naour M; Leclerc V; Farce A; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Lonchampt M; Dacquet C; Ktorza A; Berthelot P; Lebegue N
    ChemMedChem; 2012 Dec; 7(12):2179-93. PubMed ID: 23047286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [PPAR and diabetes].
    Terauchi Y; Kadowaki T
    Nihon Rinsho; 2005 Apr; 63(4):623-9. PubMed ID: 15828230
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Gawrieh S; Chalasani N
    Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 20 years of leptin: leptin in common obesity and associated disorders of metabolism.
    DePaoli AM
    J Endocrinol; 2014 Oct; 223(1):T71-81. PubMed ID: 24973357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.